(VIANEWS) – SANOFI (SAN.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| SANOFI (SAN.PA) | €99.58 | 3.61% | 12.07% |
| VETOQUINOL (VETO.PA) | €90.50 | 0.91% | 10.37% |
| VIRBAC (VIRP.PA) | €271.50 | 0.48% | 15.51% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. SANOFI (SAN.PA)
3.61% Forward Dividend Yield and 12.07% Return On Equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.85.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 14.54. Meaning, the purchaser of the share is investing €14.54 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.07%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SANOFI’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
SANOFI’s stock is valued at €99.58 at 17:30 EST, below its 52-week high of €105.18 and way above its 52-week low of €77.01.
More news about SANOFI.
2. VETOQUINOL (VETO.PA)
0.91% Forward Dividend Yield and 10.37% Return On Equity
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Earnings Per Share
As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.06.
PE Ratio
VETOQUINOL has a trailing twelve months price to earnings ratio of 22.29. Meaning, the purchaser of the share is investing €22.29 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.37%.
Moving Average
VETOQUINOL’s worth is above its 50-day moving average of €89.64 and higher than its 200-day moving average of €86.61.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VETOQUINOL’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
VETOQUINOL’s stock is valued at €90.50 at 17:30 EST, way below its 52-week high of €128.00 and way above its 52-week low of €77.00.
More news about VETOQUINOL.
3. VIRBAC (VIRP.PA)
0.48% Forward Dividend Yield and 15.51% Return On Equity
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Earnings Per Share
As for profitability, VIRBAC has a trailing twelve months EPS of €14.39.
PE Ratio
VIRBAC has a trailing twelve months price to earnings ratio of 18.87. Meaning, the purchaser of the share is investing €18.87 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.51%.
Moving Average
VIRBAC’s worth is below its 50-day moving average of €296.15 and below its 200-day moving average of €273.20.
Volume
Today’s last reported volume for VIRBAC is 816 which is 80.28% below its average volume of 4138.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 26, 2023, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 0.48%.
More news about VIRBAC.
